Recent Headlines
AnaSpec Introduces Fifteen New Catalog Peptides
AnaSpec introduced fifteen (15) new peptides for drug discovery research. - October 04, 2007 - AnaSpec, EGT Group
World-Renowned Physician and HIV Researcher Joins Samaritan's Advisory Board
Samaritan announced today the appointment of James E.K. Hildreth, M.D., a world renowned physician and HIV researcher, to its Scientific Advisory Board. The work of Dr. Hildreth in HIV/AIDS dates back to 1986 and focuses on blocking HIV infection by learning how HIV gets into cells. He has published more than 80 scientific articles and holds six patents. - October 03, 2007 - Samaritan Pharmaceuticals
AnaSpec Has Introduced a Collection of Dye-Labeled Amino Acids and Resins
AnaSpec, one of the world’s leading providers of dye-labeled and FRET (fluorescent resonance energy transfer) peptides, has introduced a collection of dye-labeled amino acids and resins. Already conjugated with fluorescent dyes or quencher molecules, these ready-to-use building blocks... - September 27, 2007 - AnaSpec, EGT Group
AnaSpec Introduces Nine New Catalog Peptides
AnaSpec introduced nine (9) new peptides for drug discovery research - September 26, 2007 - AnaSpec, EGT Group
AnaSpec Introduces Nine New Catalog Antibodies
Continuing in its commitment to expand its antibody offerings, AnaSpec added nine (9) new antibodies to its growing collection of catalog antibodies. Anti-Estrogen Receptor-alpha (Paired 167) - Cat# 28002, 50 µg Host: rabbit polyclonal; Species Reactivity: human; monkey; chimpanzees;... - September 23, 2007 - AnaSpec, EGT Group
AnaSpec Introduces New Anti-LC Antibodies
AnaSpec has introduced its newest collection of Anti-LC antibodies that can be used as autophagosome markers. - September 21, 2007 - AnaSpec, EGT Group
AnaSpec Introduces Thirty-Two New Catalog Peptides
Today AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced thirty-two (32) new peptides for drug discovery research. - September 16, 2007 - AnaSpec, EGT Group
AnaSpec Introduces Industry’s First ACE2 Activity Assay Kit
With its reported relation to cardiovascular disease, kidney disease, and severe acute respiratory syndrome (SARS), Angiotensin I converting enzyme 2 (ACE2) has become an increasingly important therapeutic target. - September 12, 2007 - AnaSpec, EGT Group
AnaSpec Introduces New Kinase Peptide Library
AnaSpec, the key supplier of kinase peptide libraries mentioned in the articles, has announced the worldwide commercial availability of its newest kinase peptide library. - September 07, 2007 - AnaSpec, EGT Group
AnaSpec Introduces Fifty-Five New Catalog Peptides
Today AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced fifty-five (55) new peptides for drug discovery research. - September 05, 2007 - AnaSpec, EGT Group
New Labeled Antibodies: Anti-CD-3ε, Anti-CD79α
Leveraging its expertise in both detection reagents and antibodies, AnaSpec has introduced a new series of labeled Anti-CD-3ε and anti-CD79α antibodies. - August 29, 2007 - AnaSpec, EGT Group
AnaSpec Introduces Thirty-Six New Catalog Peptides
Today AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced thirty-six (36) new peptides for drug discovery research. Protease-Activated Receptor-4; PAR-4 Agonist; amide; human Amyloid Precursor Protein (APP) (667-676); Swedish mutation Colivelin AGA-(C8R)... - August 28, 2007 - AnaSpec, EGT Group
AnaSpec Introduces Industry’s Longest Wavelength Assay Kit for TACE Detection
This week AnaSpec introduced the SensoLyteTM 520 TACE Assay Kit, offering fluorescence detection at the industry’s longest wavelengths. With higher fluorescence quantum yield and longer emission wavelength, this kit shows less autofluorescence interference from test compounds and cellular... - August 28, 2007 - AnaSpec, EGT Group
AnaSpec’s Published References Passes 500
As compiled by Stanford University’s Highwire Press, the number of published papers that cite AnaSpec’s products has passed 500. - August 26, 2007 - AnaSpec, EGT Group
AnaSpec Introduces 10 New Catalog Antibodies
Continuing in its commitment to rapidly expand its antibody offerings, AnaSpec, a leading provider of integrated proteomics solutions, added ten (10) new antibodies to its growing collection of catalog antibodies. Anti-MAP1-LC3 beta (NT) - Cat# 29783, 50 µg Host:rabbit polyclonal; Species... - August 25, 2007 - AnaSpec, EGT Group
AnaSpec Introduces CEF Control Peptide Pool
One of the world’s largest providers of catalog peptides, AnaSpec introduced its CEF Control Peptide Pool. Previously available only individually, this group of peptides is now available pooled. The CEF Control Peptide Pool is a group of 32 peptides, 8-12 amino acids in length, with... - August 23, 2007 - AnaSpec, EGT Group
AnaSpec Introduces 28 New Catalog Antibodies
Continuing in its commitment to rapidly expand its antibody offerings, AnaSpec, a leading provider of integrated proteomics solutions, added twenty-eight (28) new antibodies to its growing collection of catalog antibodies. - August 22, 2007 - AnaSpec, EGT Group
Samaritan Licenses Tumor Inhibiting Cancer Drugs That Also Distinguish Cancerous Tumors to Improve on Chemotherapy
Samaritan announced that it has entered into an exclusive licensing agreement with Georgetown University for a patent covering the Peripheral Benzodiazepine Receptor (PBR) which has led to Cancer drug candidates with the ability to inhibit cancerous tumors; and an imaging technique that could possibly distinguish cancerous tumors for a more targeted and improved chemotherapy. - August 21, 2007 - Samaritan Pharmaceuticals
AnaSpec Introduces New 2007-2009 Combinatorial Chemistry Catalog
One of the world’s largest providers of unusual amino acids, today AnaSpec announced the release of its 2007-2009 Combinatorial Chemistry catalog. - August 18, 2007 - AnaSpec, EGT Group
Samaritan Licenses Method to Identify Novel Anti-Tumor Drugs to Increase Cancer Compounds in Pipeline
Samaritan Pharmaceuticals has exclusively licensed a patent application entitled "Structure Based Drug Design of Steroid Inhibitors" from Georgetown University. - August 16, 2007 - Samaritan Pharmaceuticals
Analytical Results Highlight Efficacy of AnaSpec MOG Peptides
Reporting on results gathered from its antibody and assay kit departments, AnaSpec has released data that supports the efficacy of its MOG(35-55) peptide. Analytical results reported the following: AnaSpec’s mouse/rat MOG(35-55) peptide induced EAE in C57BL/6 mice with 100% incident (10/10). - July 28, 2007 - AnaSpec, EGT Group
AnaSpec Introduces Acetylated and Methylated Lysines
AnaSpec has introduced acetylated, mono-methylated, di-methylated and tri-methylated Lysine for the synthesis of histone peptides. The use of these building blocks, although not limited to making synthetic histone peptides, provides additional tools for researchers to help unravel the... - July 28, 2007 - AnaSpec, EGT Group
AnaSpec Introduces Fourteen New Catalog Peptides
Today AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced fourteen (14) new peptides for drug discovery research. HIV Nef (68–76) - Cat# 61673 This HIV nef peptide 68 to 76 amino acids was identified in HIV-infected individuals. It is a B7... - July 27, 2007 - AnaSpec, EGT Group
AnaSpec Introduces 12 New Catalog Antibodies
Continuing in its commitment to rapidly expand its antibody offerings, AnaSpec, a leading provider of integrated proteomics solutions, added twelve (12) new antibodies to its growing collection of catalog antibodies. The targeted research area for these antibodies is signal transduction and matrix... - July 26, 2007 - AnaSpec, EGT Group
AnaSpec Introduces Ten New Catalog Peptides
Today AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced ten (10) new peptides for drug discovery research. MUC4 - Cat# 61339 This peptide is derived from the tandem repeat of Muc 4 mucin protein. Mucins are highly O-glycosylated proteins which... - July 25, 2007 - AnaSpec, EGT Group
Xcelience Expanding Operations
The Tampa-based contract research organization acquires a brand new building. - July 23, 2007 - Xcelience, LLC
AnaSpec Introduces Eleven New Catalog Peptides
This week AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced eleven (11) new peptides for drug discovery research. - July 22, 2007 - AnaSpec, EGT Group
AnaSpec Introduces New Selection of Cathelicidin Peptides
Cathelicidins are cationic peptides that have broad-range antimicrobial activity. These peptides belong to the family of anti-microbial peptides which form part of the host’s important innate immunity mechanism. - July 20, 2007 - AnaSpec, EGT Group
AnaSpec Introduces Anti-MMP-1 & Anti-MMP-13 (Hinge) Antibodies
AnaSpec has introduced its newest antibody solutions – anti-MMP-1 (Hinge) and anti-MMP-13 (Hinge) antibodies. Strategically raised against the hinge regions of MMP-1 and MMP-13, the epitopes do not overlap the catalytic domain and will not influence the activity of the MMP ferment in... - July 19, 2007 - AnaSpec, EGT Group
American Peptide Symposium Poster Describes Synthesis of Hydrocarbon-Stapled Peptides
At the 2007 annual conference of the American Peptide Society, AnaSpec presented a technical poster that described the facile synthesis of a hydrocarbon-stapled peptide. Asymmetric synthesis of (S)-Fmoc-α-(2’-pentenyl)-alanine was successfully accomplished via an Ala-Ni (II)-BPB-complex... - July 14, 2007 - AnaSpec, EGT Group
AnaSpec Presents Late-Breaking In Vivo Imaging Poster at American Peptide Symposium
At the 2007 annual conference of the American Peptide Society, AnaSpec presented a “late-breaking” technical poster that described in vivo imaging using a tissue-specific near infrared fluorescent peptide conjugate. Extracellular matrix proteins that contain the Arg-Gly-Asp (RGD)... - July 13, 2007 - AnaSpec, EGT Group
PharmaChem Publishes AnaSpec Article on Peptides as Antigens
The June issue of PharmaChem, an Italian journal covering the drug discovery industry, featured an article written by AnaSpec called “Peptides as Antigens.” The technical article, written by Dr. Daniel Li and Cecilia Po, outlines the advantages and methodologies behind using peptides as... - June 24, 2007 - AnaSpec, EGT Group
AnaSpec Introduces New SensoLyte™ Beta-Secretase Assay Kit
Leveraging one of the world’s largest collections of amyloid peptides, AnaSpec has introduced its latest development in novel solutions for amyloid-related research - the new SensoLyte™ 520 Beta-Secretase Assay Kit. Beta-secretase catalyzes a key step in the production of beta-amyloid... - June 22, 2007 - AnaSpec, EGT Group
AnaSpec Introduces Industry’s First and Only Anti-MOG ELISA Kits
Drawing on its broad portfolio of MOG (35-55) and other multiple sclerosis (MS) experimental autoimmune encephalomyelitis (EAE)-related peptides, AnaSpec has just released its new line of SensoLyte™ Anti - MOG ELISA Kits - the industry’s first and only anti-MOG ELISA kits. Myelin... - June 16, 2007 - AnaSpec, EGT Group
AnaSpec Prepares Technical Poster about Beta-Secretase Assay for Experimental Biology 2007
At the 2007 Experimental Biology conference in Washington, DC, AnaSpec prepared a technical poster entitled, "A Sensitive Fluorimetric Assay for Detection of beta-Secretase Activity Using a Novel FRET Peptide Substrate." The poster documented the following findings: • A highly... - June 08, 2007 - AnaSpec, EGT Group
Novel Agent for Reactive Metabolite Detection
Bioactivation of drug candidates resulting in chemically reactive, electrophilic metabolites have always presented a major challenge to pharmaceutical companies. Moreover, the measurement of these metabolites has been hampered by the lack of an effective quantitative method. QA-GSH is a novel new... - May 31, 2007 - AnaSpec, EGT Group
Xcelience Will Acquire New Technologies to Enhance Drug Development Processes
The Tampa-based Contract Research Organization signed a partnership that will form new opportunities in the pharmaceutical industry. - May 24, 2007 - Xcelience, LLC
AnaSpec Introduces Line of Insulin Receptor Antibodies
The insulin receptor is a transmembrane receptor that belongs to the tyrosine kinase receptors class. It is a heterotetrameric glycoprotein composed of disulfide-linked subunits in a β-α-α-β configuration. This transmembrane receptor consists of 95kDa β-subunit, a single... - May 23, 2007 - AnaSpec, EGT Group
Industry’s First West Nile Virus Protease Assay Kits
While West Nile virus (WNV) has had significant outbreaks throughout the world since it was first identified, commercially available assay kits for the detection of WNV protease inhibitors had not been developed until now. With the SensoLyte™ series of WNV Protease Assay Kits AnaSpec, a... - May 17, 2007 - AnaSpec, EGT Group
Interleukin & Chemokine Antibodies – Two Types of Cytokine Antibodies
Interleukin-32 (IL-32), whose expression is increased following activation by IL-2, was initially identified as a transcript (NK4) selectively expressed in lymphocytes and NK cells.1 - April 18, 2007 - AnaSpec, EGT Group
ABRF Poster Presents Comparison of Fluorescent Peptide Synthesis Methods
At the 2007 annual conference of the Association of Biomolecular Resource Facilities, AnaSpec presented a technical poster that compared the synthesis of a fluorescent peptide using two types of resins. The results of the poster indicated that the use of an unprotected resin was just as effective... - April 13, 2007 - AnaSpec, EGT Group
New Dye Solution for Far Red to NIR Imaging
Utilizing its proprietary HiLyte Fluor™ technology, AnaSpec has introduced dye solutions for far red to NIR imaging. AnaSpec’s HiLyte Fluor™ 647, HiLyte Fluor™ 680, and HiLyte Fluor™ 750 provide AnaSpec with a range of dyes that cover the spectrum. AnaSpec has also... - April 11, 2007 - AnaSpec, EGT Group
AnaSpec Introduces AnaTag™ Protein Labeling Kits
The labeling of proteins and antibodies with fluorescent dyes can play a crucial role in flow cytometry, immunohistochemistry and fluorescent in-situ hybridization techniques. Incorporating its high performance HiLyte Fluor™ dyes in a ready-to-use kit, AnaSpec has introduce its new line of... - April 04, 2007 - AnaSpec, EGT Group
AnaSpec Launches Optimized Website
In an effort to optimize the online experience of its customers, AnaSpec, a worldwide provider of integrated proteomics solutions, has moved its website to a faster, dedicated server. AnaSpec sales & marketing manager, Violeta Rajkovska, MBA, stated, “With the huge number of catalog... - March 28, 2007 - AnaSpec, EGT Group
Two Leading Biotech Publications Report on Advaxis’ Listeria Platform Technology
Advaxis’ John Rothman Recognized as one of 20 Notable People in R&D - March 16, 2007 - Advaxis
Name Change: AnaSpec’s EnzoLyte is now SensoLyte™
AnaSpec, a worldwide provider of integrated proteomics solutions, announced today that the name of their flagship line of high-performance assay kits has been changed from EnzoLyte to SensoLyte™. AnaSpec sales & marketing manager, Violeta Rajkovska, MBA, noted, “The new name... - March 14, 2007 - AnaSpec, EGT Group
Xcelience Employs "CFS1200 Capsule Filling and Sealing Machine"
Xcelience's implementation of the CFS1200 will allow its formulation scientists the opportunity to accelerate the drug development timeframe. - March 13, 2007 - Xcelience, LLC
Xcelience Completes Successful QP Audit of Production Facility for European Market
Xcelience achives its third successful audit. - March 09, 2007 - Xcelience, LLC
Xcelience Debuts its Innovative and Interactive Forum: XpertXchange™
XpertXchange will initiate dialogue between Xcelience scientists and drug development professionals. - March 02, 2007 - Xcelience, LLC
Creating New Life Forms that May Help Eradicate Cancer Affecting Women
Instead of using the usual cancer-fighting modalities, surgery, chemotherapy, or radiation, researchers from a drug development company called Advaxis, have embarked on a novel approach to fighting cancer: Engaging the immune system to attack cancer in the same the way it would a flu vaccine, by... - February 27, 2007 - Advaxis